Miragen Therapeutics

edit

miRagen Therapeutics was founded in 2007 to improve patients’ lives by developing innovative microRNA (miRNA) based therapeutics for the treatment of cardiovascular and muscle disease. miRNAs, a recently discovered class of small RNAs encoded in the genome, are short, single-stranded RNA molecules that regulate gene expression with the potential to play a vital role in influencing the pathways responsible for cardiovascular and muscle disorders.

Located in energetic Boulder, Colorado at the foothills of the Rocky Mountains, miRagen is leveraging its core capabilities in miRNA profiling, oligonucleotide medicinal chemistry, cellular analysis, and in vivo testing in disease models to select highly potent modulators that target lead miRNAs in disease-specific pathways.

Milestones

edit

• 
  Miragen Therapeutics received $4M in Series B funding. (6/3/09)
  Posted 6/17/09 at 10:36am
• 
  Miragen Therapeutics received $8M in Series A funding. (5/19/08)
  Posted 6/7/09 at 11:48pm
• 
  Miragen Therapeutics added William S. Marshall as President & CEO.
  Posted 6/7/09 at 11:48pm
• 
  Miragen Therapeutics added Eric N. Olson as Co-Founder and Chief Scientific Advisor.
  Posted 6/7/09 at 11:48pm

Videos

Screenshots

edit

Above: Homepage
Uploaded: 6/8/09

Sources

1. Capital Funding Report [edit]
2. biospace.com [edit]